Reversing metabolic reprogramming by CPT1 inhibition with etomoxir promotes cardiomyocyte proliferation and heart regeneration via DUSP1 ADP-ribosylation-mediated p38 MAPK phosphorylation
机构:[1]Department of Cardiology, Daping Hospital, the Third Military Medical University (Army Medical University), Chongqing 400042, China.[2]Key Laboratory of Geriatric Cardiovascular and Cerebrovascular Disease Research, Ministry of Education of China, Chongqing Key Laboratory for Hypertension Research, Chongqing Cardiovascular Clinical Research Center, Chongqing Institute of Cardiology, Chongqing 400042, China.[3]Department of Cardiovascular Medicine, the General Hospital of Western Theater Command, Chengdu 610083, China.西部战区总医院[4]Division of Renal Diseases and Hypertension, the George Washington University School of Medicine and Health Sciences, Washington, DC 20541, USA.[5]State Key Laboratory of Trauma, Burns and Combined Injury, Daping Hospital, the Third Military Medical University, Chongqing 400042, China.[6]Cardiovascular Research Center of Chongqing College, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Chongqing 400042, China.[7]Department of Cardiology, the First Affiliated Hospital of Kunming Medical University, Kunming 650000, China.内科科室心脏内科昆明医科大学附属第一医院
This study was supported by grants from the National Key
Research and Development Program of China (No.
2022YFA1104500), National Natural Science Foundation of
China (No. 81930008), Natural Science Foundation of Sichuan
Province (No. 2023NSFSC1651, China), and the National Institutes of Health (No. DK134574 and No. DK119652, US).
第一作者机构:[1]Department of Cardiology, Daping Hospital, the Third Military Medical University (Army Medical University), Chongqing 400042, China.[2]Key Laboratory of Geriatric Cardiovascular and Cerebrovascular Disease Research, Ministry of Education of China, Chongqing Key Laboratory for Hypertension Research, Chongqing Cardiovascular Clinical Research Center, Chongqing Institute of Cardiology, Chongqing 400042, China.[3]Department of Cardiovascular Medicine, the General Hospital of Western Theater Command, Chengdu 610083, China.
共同第一作者:
通讯作者:
通讯机构:[1]Department of Cardiology, Daping Hospital, the Third Military Medical University (Army Medical University), Chongqing 400042, China.[2]Key Laboratory of Geriatric Cardiovascular and Cerebrovascular Disease Research, Ministry of Education of China, Chongqing Key Laboratory for Hypertension Research, Chongqing Cardiovascular Clinical Research Center, Chongqing Institute of Cardiology, Chongqing 400042, China.[5]State Key Laboratory of Trauma, Burns and Combined Injury, Daping Hospital, the Third Military Medical University, Chongqing 400042, China.[6]Cardiovascular Research Center of Chongqing College, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Chongqing 400042, China.[7]Department of Cardiology, the First Affiliated Hospital of Kunming Medical University, Kunming 650000, China.
推荐引用方式(GB/T 7714):
Tang Luxun,Shi Yu,Liao Qiao,et al.Reversing metabolic reprogramming by CPT1 inhibition with etomoxir promotes cardiomyocyte proliferation and heart regeneration via DUSP1 ADP-ribosylation-mediated p38 MAPK phosphorylation[J].Acta Pharmaceutica Sinica B.2025,15(1):256-277.doi:10.1016/j.apsb.2024.11.001.
APA:
Tang Luxun,Shi Yu,Liao Qiao,Wang Feng,Wu Hao...&Zeng Chunyu.(2025).Reversing metabolic reprogramming by CPT1 inhibition with etomoxir promotes cardiomyocyte proliferation and heart regeneration via DUSP1 ADP-ribosylation-mediated p38 MAPK phosphorylation.Acta Pharmaceutica Sinica B,15,(1)
MLA:
Tang Luxun,et al."Reversing metabolic reprogramming by CPT1 inhibition with etomoxir promotes cardiomyocyte proliferation and heart regeneration via DUSP1 ADP-ribosylation-mediated p38 MAPK phosphorylation".Acta Pharmaceutica Sinica B 15..1(2025):256-277